SAREPTA

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

Retrieved on: 
Friday, May 3, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular disease, SRPT, National academy, DSM-IV codes, Hospital, Muscular dystrophy, Book, SMA, Cell, Duchenne, Disease, TIME, Patient, Sarepta Therapeutics, Gene, Society, Nationwide, Duchenne muscular dystrophy, Head, Therapy, Global health, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.
  • The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health.
  • In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine.
  • He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy.

IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus

Retrieved on: 
Friday, April 12, 2024
Interstate Highway System, FDA, Hospital, PPD, Research, Ohio State University, University of Wisconsin–Madison, Duchenne muscular dystrophy, University, Sarepta Therapeutics, Gene, Acquisition, Abbott Laboratories, Nationwide Children's Hospital, GMP, Easton Town Center, IRA, Pharmaceutical industry

Irvine, California--(Newsfile Corp. - April 11, 2024) - IRA Capital ("IRA"), a Southern California-based real estate private equity firm, is pleased to announce the acquisition of a 237,000 square-foot life science campus consisting of four, 3-story interconnected buildings located within Columbus Ohio's highly desired Easton submarket.

Key Points: 
  • Irvine, California--(Newsfile Corp. - April 11, 2024) - IRA Capital ("IRA"), a Southern California-based real estate private equity firm, is pleased to announce the acquisition of a 237,000 square-foot life science campus consisting of four, 3-story interconnected buildings located within Columbus Ohio's highly desired Easton submarket.
  • Sarepta specializes in genetic medicines for rare diseases and has four FDA approved drugs treating Duchenne Muscular Dystrophy, including its flagship treatment Elevydis.
  • Mr. Kasm explained that "Life Science companies with a presence in markets like Madison and Columbus benefit from lower operating costs and can leverage local fundamental drivers that generate efficiency.
  • IRA closed the acquisition on an all-cash basis and is actively pursuing additional life science opportunities.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, April 30, 2024
Health, FDA, Genetics, Other Science, Research, Science, Pharmaceutical, SRPT, Compensated emancipation, Therapy, Employment

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 0 shares of Sarepta's common stock, and in the aggregate 17,090 restricted stock units (“RSUs”).
  • The options have an exercise price of $126.66 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2024 (the “Grant Date”).

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, April 24, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, SRPT, Therapy, PIN, Interest

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024.
  • Subsequently, at 4:30 p.m.
  • E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.
  • Interested parties participating by phone will need to register using this online form .

Global Cell and Gene Therapy Markets Report 2024-2028: Focus on Zolgensma, Yescarta, Kymriah, Abecma, Maci, Tecartus, Epicel - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Health, Genetics, Growth, PTC Therapeutics, Prevalence, Gene editing, ESG, CSL Behring, Roche, Etranacogene dezaparvovec, Gene, Gilead Sciences, Cancer, Eladocagene exuparvovec, Therapy, CRISPR, Mallinckrodt, PTC, Probability, BLA, Pharmaceutical industry

The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cell and Gene Therapy Market is expected to grow at a compound annual growth rate (CAGR) of 26.40% from 2023 through 2028.
  • The scope of this study encompasses an investigation of the cell and gene therapy market.
  • The report analyzes cell and gene therapy market based on therapy type, product, application, and region.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 29, 2024
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Employment, Compensated emancipation, SRPT, Therapy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 5,100 shares of Sarepta's common stock, and in the aggregate 9,335 restricted stock units (“RSUs”).
  • The options have an exercise price of $129.46 per share, which is equal to the closing price of Sarepta's common stock on March 29, 2024 (the “Grant Date”).

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, March 4, 2024
Health, FDA, Genetics, Research, Science, Pharmaceutical, Biotechnology, SRPT, Therapy, Fontainebleau Miami Beach, Software, Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming investor conferences:
    Leerink Partners Global Biopharma Conference on Mon., March 11, 2024, at 10:00 a.m. E.T at the Fontainebleau Hotel in Miami, Fla.
    Barclays 26th Annual Global Healthcare Conference on Tue., March 12, 2024, at 3:05 p.m. E.T.
  • at the Loews Miami Beach Hotel in Miami, Fla.
  • The presentations will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days.
  • Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Destroy Duchenne selects DNA Nanobots as Partner to Develop Non-Viral Gene Delivery Solution for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, February 29, 2024
Technology, Genetics, Other Technology, Nanotechnology, Software, Other Health, Biotechnology, Hardware, General Health, Health, Therapy, Toxicity, Paralysis, FDA, DMD, Duchenne muscular dystrophy, Facial muscles, B cell, Occupational therapy, Patient, Disease, Heart, AAV, DNA, Partnership, Vaccine

Duchenne Muscular Dystrophy (DMD) is a serious progressive, fatal genetic muscle wasting disease that impacts 1 in 3,500 almost exclusively boys and over 300,000 worldwide.

Key Points: 
  • Duchenne Muscular Dystrophy (DMD) is a serious progressive, fatal genetic muscle wasting disease that impacts 1 in 3,500 almost exclusively boys and over 300,000 worldwide.
  • Current treatment options for DMD include steroid medications to maintain muscle strength, physical and occupational therapy, surgery, and viral gene therapy.
  • Elijah works with several biopharmaceutical companies and was intrigued by the targeted, non-viral full length dystrophin gene delivery approach of DNA Nanobots presented to him by DNA Nanobots Co-Founder and Chief Science Officer, Dr. Christopher Lucas.
  • “I am extremely encouraged by the promising targeted non-viral gene delivery approach that DNA Nanobots uses.

Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases

Retrieved on: 
Thursday, February 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Genetics, Clinical Trials, Duchenne, Crigler–Najjar syndrome, LGMD, Muscular dystrophy, Partnership, Food, Sarepta Therapeutics, Female, Duchenne muscular dystrophy, DSM-IV codes, Weakness, Doctor of Philosophy, Prevalence, Therapy, Muscle weakness, Patient, Disease, Male, IND, Pharmaceutical industry

Genethon , a non-profit research organization focused on developing gene therapies for rare diseases, today marks International Rare Disease Day by highlighting its efforts to bring gene therapies to patients suffering from rare diseases such as limb girdle muscular dystrophies, Crigler Najjar syndrome and Duchenne muscular dystrophy.

Key Points: 
  • Genethon , a non-profit research organization focused on developing gene therapies for rare diseases, today marks International Rare Disease Day by highlighting its efforts to bring gene therapies to patients suffering from rare diseases such as limb girdle muscular dystrophies, Crigler Najjar syndrome and Duchenne muscular dystrophy.
  • Globally more than 300 million people, most of them children, are living with 7,000 rare diseases.
  • Because patient populations are small, these diseases don’t readily fit into the biopharma industry’s business models.
  • “Despite challenges in generating interest with biopharma companies and investors, Genethon will never abandon patients suffering from rare and ultra-rare diseases,” said Dr. Revah.

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

Retrieved on: 
Thursday, February 29, 2024
University, Education, Health, Philanthropy, General Health, Hispanic, Training, Genetics, Foundation, Consumer, Continuing, SRPT, Duchenne, Duchenne muscular dystrophy, Therapy, Student, PDT, Diagnosis, Sibling, Nursing

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year.
  • “Sarepta is proud to announce the opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year.
  • Only applicants diagnosed with Duchenne or applicants who have a sibling diagnosed with Duchenne are eligible for the program.
  • Previous recipients of Route 79 scholarships may apply for the 2024 Scholarship Program, however, applicants may only receive a Route 79 scholarship up to four times.